These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 17525910

  • 1. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 2. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 3. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 4. Combined therapy with deferoxamine and deferiprone.
    Kattamis A.
    Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
    [Abstract] [Full Text] [Related]

  • 5. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.
    Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [Abstract] [Full Text] [Related]

  • 6. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Jan; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 7. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 8. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 9. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Feb; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 10. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ.
    Hemoglobin; 2008 Feb; 32(1-2):1-15. PubMed ID: 18274978
    [Abstract] [Full Text] [Related]

  • 11. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
    Huang YC, Chang JS, Wu KH, Peng CT.
    Hemoglobin; 2006 Feb; 30(2):229-38. PubMed ID: 16798648
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S, Zhang W, Huang L, Jiang H.
    PLoS One; 2013 Feb; 8(12):e82662. PubMed ID: 24376563
    [Abstract] [Full Text] [Related]

  • 13. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 14. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2006 Apr 10; 30(2):219-27. PubMed ID: 16798647
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar 10; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 16. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.
    Acta Haematol; 2010 Mar 10; 123(3):148-52. PubMed ID: 20185899
    [Abstract] [Full Text] [Related]

  • 17. Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
    Peng CT, Chang JS, Wang LY, Chiou SS, Hsiao CC, Wang SC, Hung GY, Wu KH.
    Hemoglobin; 2009 Mar 10; 33(5):304-11. PubMed ID: 19814676
    [Abstract] [Full Text] [Related]

  • 18. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 15; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 20. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Nov 15; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.